Social odor recognition: A novel behavioral model for cognitive dysfunction in Parkinson's disease

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 153-159

  Monaghan, Michael M ^a   Leddy, Lauren ^a   Sung, Mei Li Amy ^a   Albinson, Kristin ^a   Kubek, Katie ^a   Pangalos, Menelas N ^a   Reinhart, Peter H ^a   Zaleska, Margaret M ^a   Comery, Thomas A ^a  

^a PFIZER INC   (United States)

Author keywords

Memory; MPTP; Olfaction; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE TRANSPORTER; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MEMORY DISORDER; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OLFACTORY DISCRIMINATION; OLFACTORY MEMORY; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PSYCHOLOGICAL MODEL; RECOGNITION; SOCIAL ASPECT; SOCIAL OLFACTORY DISCRIMINATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXPLORATORY BEHAVIOR; MALE; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MPTP POISONING; RECOGNITION (PSYCHOLOGY); SOCIAL DOMINANCE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 77449105237     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000289227     Document Type: Conference Paper

References (24)

1. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P: A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontalstriatal circuitry. Cogn Behav Neurol 2003; 16: 193-210.
2. Grahn JA, Parkinson JA, Owen AM: The cognitive functions of the caudate nucleus. Prog Neurobiol 2008; 86: 141-155.
3. Muslimovic D, Post B, Speelman JD, Schmand B: Cognitive profiles of patients with newly diagnosed Parkinson's disease. Neurology 2005; 65: 1239-1245.
4. Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-312.
5. Bove J, Prou D, Perier C, Przedborski S: Toxin- induced models of Parkinson's disease. NeuroRx 2005; 2: 484-494.
6. Schneider JS, Kovelowski CJ: Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 1990; 519: 122-128.
7. Decamp E, Schneider JS: Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci 2004; 20: 1371-1378.
8. Sedelis M, Schwarting RK, Huston JP: Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001; 125: 109-125.
9. Liberini P, Parola S, Spano PF, Antonini L: Olfaction in Parkinson's disease: methods of assessment and clinical relevance. J Neurol 2000; 247: 88-96.
10. Spinetta MJ, Woodlee MT, Feinberg LM, Stroud C, Schallert K, Cormack LK, Schallert T: Alcohol-induced retrograde memory impairment in rats: prevention by caffeine. Psychopharmacology 2008; 201: 361-371.
11. Arias RL, Sung M-L A, Vasylyev D, Zhang M-Y, Albinson K, Kubek K, Kagen N, Beyer C, Lin Q, Dwyer JM, Zaleska MM, Bowlby MR, Dunlop J, Monaghan M: Amiloride is neuroprotective in an MPTP model of Parkinson's disease. Neurobiol Dis 2008; 31: 334-341.
12. Arakawa H, Arakawa K, Blanchard DC, Blanchard RJ: Scent marking behavior in male C57/BL/6J mice: sexual and developmental determination. Behav Brain Res 2007; 182: 73-79.
13. Sawyer TF, Hengehold AK, Perez WA: Chemosensory and hormonal mediation of social memory in male rats. Behav Neurosci 1984; 98: 908-913.
14. Terranova JP, Perio A, Worms P, Le Fur G, Soubrie P: Social olfactory recognition in rodents: deterioration with age, cerebral ischaemia and septal lesion. Behav Pharmacol 1994; 5: 90-98.
15. Tanila H, Bjorklund M, Riekkinen P: Cognitive changes in mice following moderate MPTP exposure. Brain Res Bull 1998; 45: 577-582.
16. Vuckovic MG, Wood RI, Holschneider DP, Abernathy A, Togasaki DM, Smith A, Petzinger GM, Jakowec MW: Memory, mood, dopamine, and serotonin in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 2008; 32: 319-327.
17. Dluzen DE, Kreutzberg JD: 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse. Brain Res 1993; 609: 98-102.
18. Sonsalla PK, Heikkila RE: Neurotoxic effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 345-354.
19. Seniuk NA, Tatton WG, Greenwood CE: Dose-dependent destruction of the coeruleus- cortical and nigral-striatal projections by MPTP. Brain Res 1990; 527: 7-20.
20. Brunig I, Sommers M, Hatt H, Bormann J: Dopamine receptor subtypes modulate olfactory bulb gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci 1999; 96: 2456-2460.
21. Tillerson JL, Caudle WM, Parent JM, Gong C, Schallert T, Miller GW: Olfactory discrimination deficits in mice lacking the dopaminergic transporter or D2 dopamine receptor. Behav Brain Res 2006; 172: 97-105.
22. Wilson DA, Sullivan RM: The D2 antagonist spiperone mimics the effects of olfactory deprivation on mitral/tufted cell odor response patterns. J Neurosci 1995; 15: 5574-5581.
23. German DC, Nelson EL, Liang C-L, Speciale SG, Sinton CM, Sonsalla PK: The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 1996; 5: 299-312.
24. Mitsumoto Y, Mori A, Ohashi S, Nakai M, Moriizumi T: Differential effects of 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice. Neurosci Res 2005; 51: 111-115.